Moderna Stock Surges on Positive Phase 3 Melanoma Trial Results
Shares of Moderna (NASDAQ: MRNA) surged by over 176% after the company announced positive results from a Phase 3 clinical trial for its experimental mRNA-based cancer therapy, intismeran autogene. The treatment is being developed in collaboration with Merck and aims to activate an anti-tumor immune response tailored to individual patients' tumors. The study evaluated intismeran combined with Merck's Keytruda (NASDAQ: MRK) for high-risk melanoma patients who had undergone surgery, meeting its primary endpoint of recurrence-free survival. Moderna CEO Stéphane Bancel highlighted the significance of these findings as a pivotal moment in cancer research. Moderna and Merck plan to present further data at an international medical conference and engage with regulators regarding potential filings. Additional trials are underway for other cancers, including lung, bladder, and kidney.
Topics: intismeran autogene Keytruda melanoma Merck Moderna mRNA therapy